Compass Therapeutics, Inc. – NASDAQ:CMPX

Add to watchlist

$2.73

+1.26

+86.98%

Market closed

Open in about 10 hours

+35.19%

month

+35.19%

quarter

-2.67%

year

Market Cap	209.10M
Enterprise value	330.88M

P/E	-8.85
EV/Sales	N/A
EV/EBITDA	-9.46
Price/Sales	N/A
Price/Book	1.99
PEG ratio	-0.12
EPS	-0.35

Revenue	N/A
EBITDA	-51.55M
Income	-45.44M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Compass Therapeutics, Inc. (NASDAQ:CMPX): Profit margin
Jun 2023	0	-11.27M
Sep 2023	0	-9.96M
Dec 2023	2.84M	-13.41M	-471.69%
Mar 2024	0	-10.78M

Compass Therapeutics Financials Estimate

Q Y

Compass Therapeutics, Inc. (NASDAQ:CMPX): Analyst Estimates
Dec 2023	2.84M	-13.41M	-471.69%
Mar 2024	0	-10.78M
Oct 2025	0	-12.29M
Dec 2025	0	-12.29M

Analysts Price target
Financials & Ratios estimates

Compass Therapeutics, Inc. (NASDAQ:CMPX): Earnings per share (EPS)
2023-11-09	-0.11	-0.08
2024-03-21	-0.09	-0.11
2024-05-13	-0.11	-0.08

Compass Therapeutics, Inc. (NASDAQ:CMPX): Debt to assets
Jun 2023	179181000	10.89M	6.08%
Sep 2023	170038000	9.99M	5.88%
Dec 2023	156875000	8.33M	5.31%
Mar 2024	161142000	4.08M	2.53%

Compass Therapeutics, Inc. (NASDAQ:CMPX): Cash Flow
Jun 2023	-10.11M	-667K	3.03M
Sep 2023	-5.92M	17.04M	21K
Dec 2023	-12.35M	6.31M	-158K
Mar 2024	-13.88M	-4.09M	17.43M

Compass Therapeutics alternative data

Compass Therapeutics
Employees

Compass Therapeutics, Inc. (NASDAQ:CMPX): Employee count
Sep 2023	26
Oct 2023	26
Nov 2023	26
Dec 2023	26
Jan 2024	26
Feb 2024	26
Mar 2024	26
Apr 2024	26
May 2024	26
Jun 2024	32
Jul 2024	32

Compass Therapeutics
Hedge Funds Holdings Q1 2023

20.93% -58.23%

of CMPX is owned by hedge funds

32 -23

hedge funds hold CMPX stock

21.10M -58.72M

shares is hold by hedge funds

CMPX hedge funds holdings changes

Compass Therapeutics
Insider Trading

Compass Therapeutics, Inc. (NASDAQ:CMPX): Insider trades (number of shares)
Period	Buy	Sel
May 2022	520332	0
Jun 2022	120000	0
Aug 2022	45000	0
Sep 2022	55000	0
Nov 2022	804000	46761
Jan 2023	40000	0
Feb 2023	40000	0
Mar 2023	10000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	10 Mar 2023	SCHUETZ THOMAS J. director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	10,000	$3.37	$33,700
Purchase	27 Feb 2023	SCHUETZ THOMAS J. director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	20,000	$3.98	$79,600
Purchase	15 Feb 2023	SCHUETZ THOMAS J. director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	20,000	$3.86	$77,200
Purchase	31 Jan 2023	SCHUETZ THOMAS J. director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	20,000	$4.05	$81,000
Purchase	24 Jan 2023	SCHUETZ THOMAS J. director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	20,000	$4.19	$83,800
Sale	25 Nov 2022	BISKER-LEIB VERED officer: Chief Op..	Common Stock	2	$4.36	$9
Sale	23 Nov 2022	BISKER-LEIB VERED officer: Chief Op..	Common Stock	9,569	$4.3	$41,147
Sale	22 Nov 2022	BISKER-LEIB VERED officer: Chief Op..	Common Stock	14,929	$4.19	$62,553
Sale	21 Nov 2022	BISKER-LEIB VERED officer: Chief Op..	Common Stock	16,035	$4.34	$69,592
Sale	18 Nov 2022	BISKER-LEIB VERED officer: Chief Op..	Common Stock	6,226	$4.4	$27,394

CMPX insider trading transactions

Compass Therapeutics
Executives

Insider	Age	Since	Compensation
Dr. Vered Bisker-Leib Ph.D., MBA (1971) Pres & Chief Operating Officer	54		$520,000
Dr. Thomas J. Schuetz M.D., Ph.D. (1961) Co-Founder, Chief Executive Officer & Director	64		$4,000

Compass Therapeutics
Latest News

Tuesday, 10 December 2024
10:41	Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?	zacks.com
08:00	Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer	globenewswire.com
Monday, 9 December 2024
12:54	Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer	seekingalpha.com
Monday, 2 December 2024
08:00	Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference	globenewswire.com
Thursday, 21 November 2024
10:35	Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)	zacks.com
Friday, 15 November 2024
13:00	What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock	zacks.com
Wednesday, 13 November 2024
08:30	Compass Therapeutics to Participate in Upcoming Investor Events	globenewswire.com
Tuesday, 12 November 2024
08:00	Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update	globenewswire.com
Friday, 8 November 2024
10:05	Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting	globenewswire.com
Friday, 4 October 2024
10:31	Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting	globenewswire.com
Tuesday, 3 September 2024
08:00	Compass Therapeutics to Participate in Upcoming Investor Events	globenewswire.com
Wednesday, 7 August 2024
08:00	Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference	globenewswire.com
Wednesday, 10 July 2024
13:00	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why	zacks.com
Thursday, 20 June 2024
03:14	Compass Therapeutics: Pointing Right At Some Tough Cancers	seekingalpha.com
Thursday, 30 May 2024
08:00	Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference	globenewswire.com
Tuesday, 28 May 2024
16:10	Compass Therapeutics Announces CEO Transition	globenewswire.com
Thursday, 23 May 2024
17:05	Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024	globenewswire.com
Tuesday, 14 May 2024
08:00	Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	globenewswire.com
Monday, 13 May 2024
08:00	Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update	globenewswire.com
Friday, 12 April 2024
08:00	Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference	globenewswire.com
Wednesday, 10 April 2024
08:00	Compass Therapeutics to Participate in the Stifel Targeted Oncology Days	globenewswire.com
Tuesday, 9 April 2024
12:00	Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting	globenewswire.com
Sunday, 24 March 2024
16:00	3 Penny Stocks With the Power to 10X Your $1K Investment	InvestorPlace
Thursday, 8 February 2024
13:01	Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know	Zacks Investment Research
Tuesday, 14 November 2023
11:19	Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner	Zacks Investment Research
Tuesday, 22 November 2022
08:00	Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference	GlobeNewsWire
Tuesday, 8 November 2022
08:00	Compass Therapeutics to Present at Upcoming Investment Conferences	GlobeNewsWire
Friday, 9 September 2022
08:00	Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference	GlobeNewsWire
Monday, 23 May 2022
08:00	Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference	GlobeNewsWire
Tuesday, 3 May 2022
16:01	Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 13 Aug 2025

Compass Therapeutics: Finding Their Way With More Positive Updates In BTC
Seeking Alpha 13 May 2025

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers
Seeking Alpha 20 Jun 2024

Compass Therapeutics: Pointing Right At Some Tough Cancers

Frequently Asked Questions (FAQ)

What's the price of Compass Therapeutics stock today?

One share of Compass Therapeutics stock can currently be purchased for approximately $2.73.
When is Compass Therapeutics's next earnings date?

Unfortunately, Compass Therapeutics's (CMPX) next earnings date is currently unknown.
Does Compass Therapeutics pay dividends?

No, Compass Therapeutics does not pay dividends.
How much money does Compass Therapeutics make?

Compass Therapeutics has a market capitalization of 209.10M. Compass Therapeutics made a loss 42.49M US dollars in net income (profit) last year or -$0.08 on an earnings per share basis.
What is Compass Therapeutics's stock symbol?

Compass Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "CMPX".
What is Compass Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Compass Therapeutics?

Shares of Compass Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Compass Therapeutics's key executives?
Compass Therapeutics's management team includes the following people:
- Dr. Vered Bisker-Leib Ph.D., MBA Pres & Chief Operating Officer(age: 54, pay: $520,000)
- Dr. Thomas J. Schuetz M.D., Ph.D. Co-Founder, Chief Executive Officer & Director(age: 64, pay: $4,000)
Is Compass Therapeutics founder-led company?

Yes, Compass Therapeutics is a company led by its founder Dr. Thomas J. Schuetz M.D., Ph.D..
How many employees does Compass Therapeutics have?

As Jul 2024, Compass Therapeutics employs 32 workers, which is 23% more then previous quarter.
When Compass Therapeutics went public?

Compass Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 5 Apr 2021.
What is Compass Therapeutics's official website?

The official website for Compass Therapeutics is compasstherapeutics.com.
Where are Compass Therapeutics's headquarters?

Compass Therapeutics is headquartered at 80 Guest Street, Boston, MA.
How can i contact Compass Therapeutics?

Compass Therapeutics's mailing address is 80 Guest Street, Boston, MA and company can be reached via phone at +61 75008099.

Compass Therapeutics, Inc.

compasstherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

+61 75008099

80 Guest Street
Boston, MA 02135

CIK: 0001738021
ISIN: US20454B1044
CUSIP: 20454B104